FIT Cancer 11 11th FORUM ON Translational Immunology and IMMUNOTHERAPY OF CANCER 14 CP-05. NON-CONVENTIONAL AND ANTITUMORAL ROLE OF TISSUE-RESIDENT TCR?? Ángela Zarco Cuadrillero1, Nicolás Veland2, Bethania García-Cassani1, Miguel Muñoz Ruiz1 1Department of Immunology, Ophthalmology and ENT. School of Medicine. Universidad Complutense de Madrid. 12 de Octubre Health Research Institute (i+12). Madrid, Spain. 2Immunosurveillance Laboratory. The Francis Crick Institute. London, England CP-06. EFFECTS OF LCOR OVEREXPRESSION ON GROWTH AND IMMUNITY IN HER2+ BREAST CANCER EXPRESSION Laura Batlle Ibáñez1, Fabricio Gerel Quimis1, Silvia Menéndez1, Anna Hernández Prat1, Gabriel Serra Mir1, José Ángel Palomeque1, Pau Torrén1, Mengjuan Qin1, Sonia Servitja2, Aura Muntasell1, Ana Rovira1, Toni Celià-Terrassa1, Joan Albanell2 1Cancer Research Programe. Hospital del Mar Research Institute (IMIM). Barcelona. 2Medical Oncology Department. Hospital del Mar. CIBERONC. Barcelona CP-07. IMPACT OF PALBOCICLIB COMBINED WITH HER2-TARGETING THERAPIES ON NK CELL-MEDIATED CYTOTOXICITY IN HER2-POSITIVE BREAST CANCER CELLS Mengjuan Qin1, Jesús Suárez-Olmos2, Sara Santana-Hernández1, Anna Hernández-Prat1, Silvia Menéndez1, Lara Nonell3, Júlia Perera-Bel4, Ariadna Acedo-Terrades4, Fabricio Quimis-Ascencio4, Laura Ibáñez-Batlle1, Federico Rojo1, Aura Muntasell5, Ana Rovira1, Joan Albanell2 1Cancer Research Program. Hospital del Mar Medical Research Institute. Barcelona. 2Centro de Investigación Biomédica en Red de Cáncer (CIBERonc). Madrid. 3Pathology Department. Hospital del Mar. Barcelona. 4MARGenomics. Hospital del Mar. Medical Research Institute. Barcelona. 5Pathology Department. IIS-Fundación Jiménez Díaz. CIBERONC. Madrid CP-08. ROLE OF IMMUNE CHECKPOINT PATHWAYS (PDL1/PD1 AND HLA-G/ILT2) IN GASTRIC CANCER Alba del Valle-Reigosa1, Christian Vaquero-Yuste1, Inmaculada Lasa-Unzúe2, Adela López-García2, Remedios Gómez-Sanz2, Alberto Gutiérrez-Calvo2, José Manuel Martín-Villa1, Ignacio Juárez1 1Departamento de Inmunología, Oftalmología y ORL. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. 2Servicio de Cirugía General y del Aparato Digestivo. Hospital Universitario Príncipe de Asturias. Alcalá de Henares, Madrid CP-09. HIGH NUMBERS OF CIRCULATING CD57+ NK CELLS PREDICT RISK OF RELAPSE TO HER2-SPECIFIC THERAPEUTIC ANTIBODIES IN HER2-POSITIVE BREAST CANCER PATIENTS Sara Santana-Hernández1, Anna Hernández-Prat1, Sonia Servitja2, Marina Junyent1, Carolina Domínguez-Berzosa3, Natalia Ramírez4, María Castro2, Begoña Bermejo5, María Teresa Martínez5, Juan Cejalvo5, Federico Rojo3, Ana Rovira1, Joan Albanell2, Aura Muntasell1 1Hospital del Mar Research Institute (IMIM). Barcelona. 2Oncology Department. Hospital del Mar. Barcelona. 3Department of Pathology. Instituto de Investigación Sanitaria La Fe. València. 4Department of Oncology. IIS Fundación Jiménez Díaz. Madrid. Hospital Universitario Infanta Elena. Valdemoro, Madrid. 5Department of Oncology. Hospital Clínic de Valéncia. València CP-10. OBESITY AND OVERWEIGHT IS ASSOCIATED WITH A BETTER RESPONSE TO TREATMENT IN R/R DLBCL: POTENTIAL ROLE OF NK CD8+ CELLS AND VITAMIN D Lourdes Hontecillas-Prieto1-3, Daniel J. García-Domínguez2,3, Carlos Jiménez-Cortegana2, Esteban Nogales-Fernández3,5, Natalia PalazónCarrión3,5, Alejandro Martín García-Sancho6, Eduardo Ríos-Herranz7, Josep Gumà-Padrò8, Mariano Provencio-Pulla9, Antonio RuedaDomínguez10, Luis de la Cruz-Merino3-5, Víctor Sánchez-Margalet1,2,4
RkJQdWJsaXNoZXIy OTI4NTYw